Is Auvelity (dextromethorphan‑bupropion) FDA‑approved for treating agitation in elderly patients with dementia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 3, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Auvelity Is NOT FDA-Approved for Agitation in Dementia

Your information is incorrect—Auvelity (dextromethorphan-bupropion) is FDA-approved ONLY for Major Depressive Disorder (MDD) in adults, not for agitation in dementia patients. 1

Current FDA-Approved Indication

The FDA label explicitly states: "AUVELITY is a prescription medicine used to treat a certain type of depression called Major Depressive Disorder (MDD) in adults" and clearly notes "Auvelity is not approved for uses other than the treatment of MDD." 1

Why the Confusion May Exist

While research literature discusses dextromethorphan-bupropion combinations as being "in development" for Alzheimer's disease agitation 2, 3, this reflects investigational use only—not regulatory approval. The compound has been studied in clinical trials for agitation associated with Alzheimer's disease, but these trials have not resulted in FDA approval for this indication as of the most recent label update.

What IS Actually Approved for Dementia Agitation

For agitation in dementia patients, the evidence-based approach prioritizes:

  • Nonpharmacological interventions first (trigger identification, environmental modifications) 4, 5
  • Brexpiprazole has the strongest regulatory approval and evidence base for agitation associated with Alzheimer's dementia 5
  • Antipsychotics (risperidone, aripiprazole) may be used cautiously despite black box warnings, with careful monitoring for cerebrovascular events and mortality risk 6, 5
  • Oral quetiapine showed the best safety profile among medications for severe agitation in older adults 4

Critical Safety Concern

Using Auvelity off-label for dementia agitation would be particularly problematic because:

  • The pharmacokinetics have not been studied in patients ≥65 years 1
  • Both components carry seizure risk, which is elevated in elderly patients with dementia
  • No safety or efficacy data exist for this specific population and indication

Bottom line: Auvelity remains approved exclusively for MDD in adults. Any use for dementia-related agitation would be off-label and unsupported by FDA approval or adequate geriatric safety data.

References

Related Questions

Is Auvelity (dextromethorphan/bupropion) appropriate for treating agitation in an elderly patient with dementia, and what dosing and monitoring are recommended?
In elderly patients with dementia who have difficulty sleeping, does Auvelity (dextromethorphan/bupropion) improve sleep?
Which ADHD stimulant can be safely taken with Auvelity (dextromethorphan/bupropion)?
What are the indications and contraindications for Auvelity (dextromethorphan/bupropion)?
Is Auvelity (dextromethorphan‑bupropion) appropriate for treating binge eating in a patient with schizophrenia?
What is the drug of choice for angular cheilitis (cheilosis)?
What are the movements of the hip joint and which thigh and gluteal muscles produce each movement?
What is the appropriate management and treatment duration for Staphylococcus lugdunensis bacteremia, including antibiotic selection and necessary investigations?
What is the appropriate evaluation and management for hair loss in a 35-year-old female?
What is the appropriate enoxaparin dosing for therapeutic anticoagulation and venous thrombo‑embolism prophylaxis, including adjustments for renal function?
Is Auvelity (dextromethorphan hydrobromide / bupropion hydrochloride extended‑release) FDA‑approved for treating agitation associated with Alzheimer’s disease dementia in adults?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.